Materias dentro de su búsqueda.
Mostrando 1,901 - 1,920 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 1.18s Limitar resultados
  1. 1901
    “…Recent studies have demonstrated that HER2 and MET receptor tyrosine kinases are co-overexpressed in a subset esophageal adenocarcinoma (EAC). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma
  2. 1902
    por Ongsri, Punyawee, Varothai, Supenya
    Publicado 2019
    “…We present a rare case of familial glomuvenous malformations, a healthy young female presented with multiple bluish papules since birth which later developed dissemination later in her adolescence. Moreover, her father also had similar skin lesions on his left lower back.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Multiple Bluish Nodules in a 20-Year-Old Female with Similar Lesions in Her Father
  3. 1903
    “…BACKGROUNDS: HER-2 positive breast cancer is a subtype of breast cancer with poor clinical outcome. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Identification of potential key genes for HER-2 positive breast cancer based on bioinformatics analysis
  4. 1904
    “…DAS has shown activity in human epidermal growth factor receptor 2 (HER2) positive tumors, so conjugation of this compound with the anti-HER2 antibody trastuzumab (TAB) with the use of nanocarriers could improve its efficacy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Trastuzumab-Targeted Biodegradable Nanoparticles for Enhanced Delivery of Dasatinib in HER2+ Metastasic Breast Cancer
  5. 1905
    “…BACKGROUND: Hormone receptor (HR) and human epidermal growth factor receptor (HER2) discordance between primary and metastatic breast cancer lesions is common. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients
  6. 1906
    “…METHODS: To identify potential resistance mechanisms, we used the mouse MMTV-NIC-PTEN(+/−) spontaneous model of HER2-positive breast cancer and the pan-HER family kinase inhibitor sapatinib. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies
  7. 1907
    “…OBJECTIVE: To investigate the frequency and prognostic role of the human epidermal growth factor receptor 2 gene (HER2) and BRAF V600E gene mutation in Chinese patients with colorectal cancer (CRC). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China
  8. 1908
    por Mitani, Seiichiro, Kawakami, Hisato
    Publicado 2020
    “…Trastuzumab, a monoclonal antibody to human epidermal growth factor receptor 2 (HER2), has improved survival in patients with HER2-positive advanced gastric or gastroesophageal junction cancer (AGC). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance
  9. 1909
    “…Human epidermal growth factor receptor type 3 (HER3) is an emerging therapeutic target in several malignancies. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules
  10. 1910
    “…Human epidermal growth factor receptor 2 (HER2) is implicated in several cancers, including gastric cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2 as a potential biomarker of lymph node metastasis in undifferentiated early gastric cancer
  11. 1911
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    SLC26A3 mutation in Turkish neonate and her sibling with congenital chloride diarrhea
  12. 1912
    “…BACKGROUND: HER2 status is a predictive biomarker of response to trastuzumab in advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Impact of HER2 status in resected gastric or gastroesophageal junction adenocarcinoma in a Western population
  13. 1913
    “…Human epidermal growth factor receptor 2 (HER2) is overexpressed in over 20% of breast cancers. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Transformable peptide nanoparticles arrest HER2 signalling and cause cancer cell death in vivo
  14. 1914
    “…We applied this approach to detect HER2(+) cancer cells using the anti‐HER2 antibody (trastuzumab) coupled to initiator DNA eliciting a HCR cascade that leads to a fluorescent signal at the cell surface. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Detection of HER2(+) Breast Cancer Cells using Bioinspired DNA‐Based Signal Amplification
  15. 1915
    “…Herein, we aim to evaluate the prognostic value of IGF-1 and metabolic abnormalities in HER2+ population. Patients and Methods: HER2+ breast cancer patients treated in Ruijin Hospital between November 2012 and June 2017 were retrospectively analyzed. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    IGF-1 Interacted With Obesity in Prognosis Prediction in HER2-Positive Breast Cancer Patients
  16. 1916
    “…Methods: We identified all consecutive female patients with MBC who received any chemotherapeutic intervention for metastatic disease at our institution between July 2012 and December 2017, excluding patients with HER2-positive disease. Those who received eribulin monotherapy for MBC were classified under the eribulin cohort, whereas those who never received eribulin were included in the non-eribulin (Non-E) cohort. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Use of eribulin as an earlier-line chemotherapy for patients with HER2-negative metastatic breast cancer
  17. 1917
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Her Majesty’s Desert Throne: The Ecology of Queen Butterfly Oviposition on Mojave Milkweed Host Plants
  18. 1918
    por Chapman, Adrian
    Publicado 2018
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    “May all Be Shattered into God”: Mary Barnes and Her Journey through Madness in Kingsley Hall
  19. 1919
    “…BACKGROUND: Cholangiocarcinoma (CCA) is a slowly progressing but highly aggressive malignancy. Targeting the HER protein family represents a potential therapeutic strategy for CCA treatment. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    In vitro and in vivo Anti-Tumor Effects of Pan-HER Inhibitor Varlitinib on Cholangiocarcinoma Cell Lines
  20. 1920
    “…PURPOSE: The aim of this study was to investigate the monitoring value of serum HER2 in patients with metastatic breast cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Monitoring Value of Serum HER2 as a Predictive Biomarker in Patients with Metastatic Breast Cancer
Herramientas de búsqueda: RSS